{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:45:46Z","timestamp":1787316346000,"version":"build-2736575974"},"posted":{"date-parts":[[2024,4,3]]},"group-title":"Oncology","reference-count":54,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,4,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Individualized treatment decisions for patients with multiple myeloma (MM) requires accurate risk stratification that takes into account patient-specific consequences of genetic abnormalities and tumor microenvironment on disease outcome and therapy responsiveness.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Previously, SYstems Genetic Network AnaLysis (SYGNAL) of multi-omics tumor profiles from 881 MM patients generated the mmSYGNAL network, which uncovered different causal and mechanistic drivers of genetic programs associated with disease progression across MM subtypes. Here, we have trained a machine learning (ML) algorithm on activities of mmSYGNAL programs within individual patient tumor samples to develop a risk classification scheme for MM that significantly outperformed cytogenetics, International Staging System, and multi-gene biomarker panels in predicting risk of PFS across four independent patient cohorts.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We demonstrate that, unlike other tests, mmSYGNAL can accurately predict disease progression risk at primary diagnosis, pre- and post-transplant and even after multiple relapses, making it useful for individualized dynamic risk assessment throughout the disease trajectory.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>mmSYGNAL provides improved individualized risk stratification that accounts for a patient\u2019s distinct set of genetic abnormalities and can monitor risk longitudinally as each patient\u2019s disease characteristics change.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2024.04.01.24305024","type":"posted-content","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T22:45:10Z","timestamp":1712184310000},"source":"Crossref","is-referenced-by-count":3,"title":["Individualized dynamic risk assessment for multiple myeloma"],"prefix":"10.64898","author":[{"given":"Carl","family":"Murie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serdar","family":"Turkarslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoop","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Coffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela S.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin S.","family":"Baliga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2024040604450691000_2024.04.01.24305024v1.1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24236"},{"key":"2024040604450691000_2024.04.01.24305024v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"2024040604450691000_2024.04.01.24305024v1.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2267"},{"key":"2024040604450691000_2024.04.01.24305024v1.4","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","year":"2017","journal-title":"Nature Reviews Disease Primers"},{"issue":"2","key":"2024040604450691000_2024.04.01.24305024v1.5","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic complexity of multiple myeloma and its clinical implications","volume":"14","year":"2017","journal-title":"Nature Reviews Clinical Oncology"},{"key":"2024040604450691000_2024.04.01.24305024v1.6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-631200"},{"issue":"6","key":"2024040604450691000_2024.04.01.24305024v1.7","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s12185-022-03353-5","article-title":"Multiple myeloma with high-risk cytogenetics and its treatment approach","volume":"115","year":"2022","journal-title":"Int J Hematol"},{"issue":"22","key":"2024040604450691000_2024.04.01.24305024v1.8","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood.V128.22.374.374","article-title":"A Comparison of Clinical FISH and Sequencing Based FISH Estimates in Multiple Myeloma: An Mmrf Commpass Analysis","volume":"128","year":"2016","journal-title":"Blood"},{"key":"2024040604450691000_2024.04.01.24305024v1.9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-013458"},{"key":"2024040604450691000_2024.04.01.24305024v1.10","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10414"},{"key":"2024040604450691000_2024.04.01.24305024v1.11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.8545"},{"key":"2024040604450691000_2024.04.01.24305024v1.12","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4046"},{"key":"2024040604450691000_2024.04.01.24305024v1.13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-12-261032"},{"key":"2024040604450691000_2024.04.01.24305024v1.14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-328252"},{"key":"2024040604450691000_2024.04.01.24305024v1.15","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.127"},{"key":"2024040604450691000_2024.04.01.24305024v1.16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-038430"},{"issue":"24","key":"2024040604450691000_2024.04.01.24305024v1.17","doi-asserted-by":"crossref","first-page":"6298","DOI":"10.1182\/bloodadvances.2020002838","article-title":"Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87\/NMSG-18 trial","volume":"4","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2024040604450691000_2024.04.01.24305024v1.18","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/ijlh.13691","article-title":"Prognostic gene expression analysis in a retrospective, multinational cohort of 155 multiple myeloma patients treated outside clinical trials","volume":"44","year":"2022","journal-title":"Int J Lab Hematol"},{"issue":"1","key":"2024040604450691000_2024.04.01.24305024v1.19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bjh.16292","article-title":"Daratumumab in high-risk relapsed\/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain\/amplification and GEP70 status on outcome","volume":"189","year":"2020","journal-title":"Br J Haematol"},{"issue":"6","key":"2024040604450691000_2024.04.01.24305024v1.20","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/jth.14803","article-title":"Dynamic prediction modeling for cancer-associated venous thromboembolism","volume":"18","year":"2020","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"1","key":"2024040604450691000_2024.04.01.24305024v1.21","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3390\/cancers11010050","article-title":"Dynamic Thromboembolic Risk Modelling to Target Appropriate Preventative Strategies for Patients with Non-Small Cell Lung Cancer","volume":"11","year":"2019","journal-title":"Cancers"},{"issue":"3","key":"2024040604450691000_2024.04.01.24305024v1.22","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2019.06.011","article-title":"Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction","volume":"178","year":"2019","journal-title":"Cell"},{"key":"2024040604450691000_2024.04.01.24305024v1.23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/s12885-019-5495-6","article-title":"Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma","volume":"19","year":"2019","journal-title":"BMC Cancer"},{"issue":"10","key":"2024040604450691000_2024.04.01.24305024v1.24","doi-asserted-by":"crossref","first-page":"R553","DOI":"10.1530\/ERC-19-0213","article-title":"Dynamic risk assessment in patients with differentiated thyroid cancer","volume":"26","year":"2019","journal-title":"Endocrine-Related Cancer"},{"key":"2024040604450691000_2024.04.01.24305024v1.25","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-021-00216-w"},{"key":"2024040604450691000_2024.04.01.24305024v1.26","unstructured":"US National Institutes of Health. Relating clinical outcomes in multiple myeloma to personal assessment of genetic profile (CoMMpass). Clinical Trials website. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01454297."},{"issue":"9","key":"2024040604450691000_2024.04.01.24305024v1.27","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1038\/bcj.2012.37","article-title":"The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies","volume":"2","year":"2012","journal-title":"Blood Cancer Journal"},{"issue":"5","key":"2024040604450691000_2024.04.01.24305024v1.28","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41408-022-00673-x","article-title":"Structural variants shape the genomic landscape and clinical outcome of multiple myeloma","volume":"12","year":"2022","journal-title":"Blood Cancer J"},{"key":"2024040604450691000_2024.04.01.24305024v1.29","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1665"},{"issue":"11","key":"2024040604450691000_2024.04.01.24305024v1.30","doi-asserted-by":"crossref","first-page":"e1003323","DOI":"10.1371\/journal.pmed.1003323","article-title":"Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials","volume":"17","year":"2020","journal-title":"PLoS Med"},{"key":"2024040604450691000_2024.04.01.24305024v1.31","first-page":"PO.20.00442","article-title":"High-Throughput Drug Screening and Multi-Omic Analysis to Guide Individualized Treatment for Multiple Myeloma","volume":"5","year":"2021","journal-title":"JCO precision oncology"},{"issue":"12","key":"2024040604450691000_2024.04.01.24305024v1.32","doi-asserted-by":"crossref","first-page":"e1005887","DOI":"10.1371\/journal.pcbi.1005887","article-title":"Complete hazard ranking to analyze right-censored data: An ALS survival study","volume":"13","year":"2017","journal-title":"PLOS Computational Biology"},{"key":"2024040604450691000_2024.04.01.24305024v1.33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-9868.2005.00503.x"},{"key":"2024040604450691000_2024.04.01.24305024v1.34","unstructured":"bswhite. bswhite\/Celgene-Multiple-Myeloma-Challenge-Baseline-Models. 2019."},{"key":"2024040604450691000_2024.04.01.24305024v1.35","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.247"},{"issue":"10","key":"2024040604450691000_2024.04.01.24305024v1.36","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.1038\/bcj.2015.92","article-title":"Interpretation of cytogenetic results in multiple myeloma for clinical practice","volume":"5","year":"2015","journal-title":"Blood Cancer J"},{"key":"2024040604450691000_2024.04.01.24305024v1.37","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2586"},{"key":"2024040604450691000_2024.04.01.24305024v1.38","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-1708"},{"key":"2024040604450691000_2024.04.01.24305024v1.39","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404877"},{"key":"2024040604450691000_2024.04.01.24305024v1.40","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209974"},{"issue":"11 Pt 1","key":"2024040604450691000_2024.04.01.24305024v1.41","first-page":"3374","article-title":"Novel blood biomarkers of human urinary bladder cancer","volume":"12","year":"2006","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"4","key":"2024040604450691000_2024.04.01.24305024v1.42","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood.V80.4.887.887","article-title":"Primary dexamethasone treatment of multiple myeloma","volume":"80","year":"1992","journal-title":"Blood"},{"key":"2024040604450691000_2024.04.01.24305024v1.43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903455"},{"key":"2024040604450691000_2024.04.01.24305024v1.44","doi-asserted-by":"crossref","unstructured":"Neumeister P , Schulz E , Pansy K , Szmyra M , Deutsch AJ . Targeting the Microenvironment for Treating Multiple Myeloma. Int J Mol Sci. 2022;23(14).","DOI":"10.3390\/ijms23147627"},{"key":"2024040604450691000_2024.04.01.24305024v1.45","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3394"},{"key":"2024040604450691000_2024.04.01.24305024v1.46","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-3115"},{"issue":"9","key":"2024040604450691000_2024.04.01.24305024v1.47","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrc.2017.63","article-title":"Evolutionary biology of high-risk multiple myeloma","volume":"17","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"2024040604450691000_2024.04.01.24305024v1.48","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.197"},{"issue":"6","key":"2024040604450691000_2024.04.01.24305024v1.49","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41408-022-00695-5","article-title":"Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee","volume":"12","year":"2022","journal-title":"Blood Cancer J"},{"key":"2024040604450691000_2024.04.01.24305024v1.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2017.01.003"},{"issue":"1","key":"2024040604450691000_2024.04.01.24305024v1.51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-021-00344-2","article-title":"The changing landscape of relapsed and\/or refractory multiple myeloma (MM): fundamentals and controversies","volume":"10","year":"2022","journal-title":"Biomark Res"},{"key":"2024040604450691000_2024.04.01.24305024v1.52","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26831"},{"key":"2024040604450691000_2024.04.01.24305024v1.53","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-5725"},{"key":"2024040604450691000_2024.04.01.24305024v1.54","doi-asserted-by":"crossref","unstructured":"Shah V , Sherborne AL , Johnson DC , Ellis S , Price A , Chowdhury F , et al. Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients. Leukemia. 2020:1\u20136.","DOI":"10.1038\/s41375-020-0750-z"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.04.01.24305024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T19:57:16Z","timestamp":1768507036000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2024.04.01.24305024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,3]]},"references-count":54,"URL":"https:\/\/doi.org\/10.1101\/2024.04.01.24305024","relation":{},"subject":[],"published":{"date-parts":[[2024,4,3]]},"subtype":"preprint"}}